Accendra Health, Inc. Research and Development Expense
Accendra Health, Inc. (ACH) reported Research and Development Expense of $13.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-02-28
- Accendra Health, Inc. research and development expense for fiscal 2024 was $13.00M, a 0.00% change from fiscal 2023.
- Accendra Health, Inc. research and development expense for fiscal 2023 was $13.00M, a 8.33% increase from fiscal 2022.
- Accendra Health, Inc. research and development expense for fiscal 2022 was $12.00M, a 0.83% decline from fiscal 2021.
- Accendra Health, Inc. research and development expense for fiscal 2021 was $12.10M.
| Period end | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|
| 2024-12-31 | $13.00M 10-K · filed 2025-02-28 | |
| 2023-12-31 | $13.00M 10-K · filed 2025-02-28 | $13.20M 10-K · filed 2024-02-20 |
| 2022-12-31 | $12.00M 10-K · filed 2025-02-28 | $11.80M 10-K · filed 2024-02-20 |
| 2021-12-31 | $12.10M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HENRY SCHEIN INC (HSIC) | United States | $9.536B | 23.59 |